Identification of RCC2 as a Risk Gene Associated With Basal Cell Carcinoma and Experimental Validation
Experimental Dermatology · 2025
DOI: 10.1111/exd.70082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Dermatology, 2025. Verfasst von Yu Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Basal Cell Carcinoma, Skin Neoplasms. Die Arbeit nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shaanxi Province Science Fund for Distinguished Young Scholars, Xi 'an Jiaotong University medical "basic - clinical" fusion innovation project.
Abstract (Originalsprache)
Basal cell carcinoma (BCC) is a common type of skin cancer that is increasing in prevalence worldwide. Previous genome‐wide association studies (GWAS) have identified certain genetic loci associated with BCC. However, many potential disease‐causing genes of BCC remain to be discovered. While the sonic hedgehog (SHH) signalling pathway and mutations in PTCH1/2 and SMO are well‐established drivers of BCC pathogenesis, novel genetic factors may complement existing therapeutic targets such as vismodegib and sonidegib. The Mendelian Randomization (MR) study used multiple omics datasets including expression quantitative trait loci (eQTL), methylation quantitative trait loci (mQTL), and protein quantitative trait loci (pQTL) to identify genetic factors associated with an increased risk of developing BCC. Transcriptome analysis of the GEO database then verified the specific expression of key genes. In addition, in vitro experiments were used to silence the key gene to observe the effect of this gene on the proliferation ability of A431 cells. Combined with the multi‐omics MR Analysis results, six CpG sites were identified with the RCC2 gene associated with BCC risk. Additionally, single‐cell transcriptome analysis confirmed the specific expression of RCC2 in the BCC cohort. In the in vitro validation experiment, siRCC2‐1/2 was transfected into the A431 cells, significantly decreasing the expression of RCC2 in the cells. Moreover, the proliferation of A431 cells was significantly inhibited after RCC2 was knocked down. We identified a risk gene RCC2 associated with BCC by MR‐based bioinformatics analysis and demonstrated that inhibition of RCC2 inhibited the proliferation of A431 in vitro. These findings provide new strategies for targeted therapy of BCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- State Key Laboratory of Shaanxi for Natural Medicines Research and Engineering, Xi'an Jiaotong University, Xi'an, China.
- Department of Dermatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
ORCID-Profile: Qi Su
Förderung
- National Natural Science Foundation of China
- Shaanxi Province Science Fund for Distinguished Young Scholars
- Xi 'an Jiaotong University medical "basic - clinical" fusion innovation project
- Shaanxi Province Science and Technology Development Plan Project
- Shaanxi Province key research and development plan project
- Central University Basic Research Fund of China
- Shaanxi Innovative Talents Promotion Plan
Zitieren
APA
Zhang, Y., Han, X., Ren, J., Zhu, M., Chu, D., Zhang, Y., Su, Q., & Zhang, Z. (2025). Identification of RCC2 as a Risk Gene Associated With Basal Cell Carcinoma and Experimental Validation. Experimental Dermatology. https://doi.org/10.1111/exd.70082
Vancouver
Zhang Y, Han X, Ren J, Zhu M, Chu D, Zhang Y, et al. Identification of RCC2 as a Risk Gene Associated With Basal Cell Carcinoma and Experimental Validation. Experimental Dermatology. 2025. doi:10.1111/exd.70082
BibTeX
@article{Zhang2025,
author = {Zhang, Yu and Han, Xu and Ren, Jiayan and Zhu, Man and Chu, Dake and Zhang, Yanmin and Su, Qi and Zhang, Zixi},
title = {Identification of RCC2 as a Risk Gene Associated With Basal Cell Carcinoma and Experimental Validation},
journal = {Experimental Dermatology},
year = {2025},
doi = {10.1111/exd.70082}
}
EUVIMED